Needham & Company LLC Reaffirms Hold Rating for Envista (NYSE:NVST)

Envista (NYSE:NVST)‘s stock had its “hold” rating reaffirmed by equities researchers at Needham & Company LLC in a report released on Thursday,Benzinga reports.

A number of other analysts have also recently commented on NVST. Stifel Nicolaus boosted their target price on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Mizuho started coverage on shares of Envista in a research note on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target for the company. Jefferies Financial Group raised their price objective on Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Piper Sandler upped their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and upped their target price for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $20.21.

Envista Stock Performance

Shares of NVST stock opened at $20.58 on Thursday. The firm has a market cap of $3.54 billion, a price-to-earnings ratio of -2.65, a PEG ratio of 1.82 and a beta of 1.34. The company’s 50 day moving average is $19.97 and its 200 day moving average is $19.10. Envista has a 52-week low of $15.15 and a 52-week high of $24.79. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. On average, sell-side analysts anticipate that Envista will post 0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. boosted its position in Envista by 22.2% in the third quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock worth $69,749,000 after purchasing an additional 642,401 shares during the last quarter. Diamond Hill Capital Management Inc. grew its position in Envista by 8.1% in the third quarter. Diamond Hill Capital Management Inc. now owns 1,335,710 shares of the company’s stock worth $26,394,000 after acquiring an additional 100,360 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in Envista by 138.5% during the third quarter. Harbor Capital Advisors Inc. now owns 404,589 shares of the company’s stock valued at $7,995,000 after acquiring an additional 234,941 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista in the fourth quarter worth about $53,000. Finally, Hotchkis & Wiley Capital Management LLC bought a new stake in Envista during the 3rd quarter valued at $14,965,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.